Eli Lilly stock fell for a ninth consecutive day on December 9, 2025, raising investor concerns despite a series of positive strategic announcements. This sustained sell-off has erased approximately 10% of the company’s value over the period.
The decline continued even after Lilly announced a major strategic investment. The company committed $6 billion to build a new manufacturing facility in Alabama to boost production of its highly successful weight-loss drugs.
This new Alabama plant is set to produce key ingredients for drugs like orforglipron. The facility positions Lilly to further capitalize on the rapidly growing obesity drug market, where its products already hold significant market share. Despite this long-term growth catalyst, the market’s negative reaction suggests investors are focused on the company’s high valuation and potential competitive pressures.